APOC3 and hypertriglyceridemia: Furthermore, a recent phase 2 trial with olezarsen, a conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA in order to inhibit apoC-III production, demonstrated that olezarsen significantly reduced apoC-III, triglycerides, as well as atherogenic lipoproteins in a population with moderate hypertriglyceridemia who are either at high risk of or have established ASCVD [104].